Evidence map›Paper›PMID 38909206›Full record

ArticleRespiratory research2024

Deregulated immune cell recruitment orchestrated by c-MET impairs pulmonary inflammation and fibrosis.

Catarina Barbosa-Matos, Caroline Borges-Pereira, Sofia Libório-Ramos, Raquel Fernandes, Marcela Oliveira, Ana Mendes-Frias, Ricardo Silvestre, Nuno S Osório, Hélder N Bastos, Rita F Santos and 6 more

Abstract read
In one paragraph

Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. The transcriptome of CD14The European respiratory journal · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Catarina Barbosa-MatosLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Caroline Borges-PereiraLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Sofia Libório-RamosLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Raquel FernandesLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Marcela OliveiraLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Ana Mendes-FriasLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Ricardo SilvestreLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Nuno S OsórioLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Hélder N BastosDepartment of Pneumology, Centro Hospitalar do São João, Porto, Portugal.
Rita F Santosi3S - Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal.
Susana GuimarãesDepartment of Pathology, Centro Hospitalar Universitário de São João, Porto, Portugal.
António MoraisDepartment of Pneumology, Centro Hospitalar do São João, Porto, Portugal.
Massimiliano MazzoneLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Louvain, Belgium.
Agostinho CarvalhoLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Cristina CunhaLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Sandra CostaLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal. sandracosta@med.uminho.pt.

Funding

FCT and Stemmatters, Biotecnologia e Medicina Regenerativa SA PD/BDE/142978/2018Fundação para a Ciência e a Tecnologia 2021.07836.BDFundação para a Ciência e a Tecnologia CEECIND/00185/2020Fundação para a Ciência e a Tecnologia CEECIND/04058/2018Fundação para a Ciência e a Tecnologia PTDC/MEC-RES/0158/2020Fundação para a Ciência e a Tecnologia PTDC/MEDOUT/1112/2021Fundação para a Ciência e a Tecnologia SFRH/BD/145955/2019
6 · The paper itself

Abstract

backgroundPulmonary fibrosis (PF) represents the pathologic end stage of several interstitial lung diseases (ILDs) associated with high morbidity and mortality rates. However, current treatments can only delay disease progression rather than provide a cure. The role of inflammation in PF progression is well-established, but new insights into immune regulation are fundamental for developing more efficient therapies. c-MET signaling has been implicated in the migratory capacity and effector functions of immune cells. Nevertheless, the role of this signaling pathway in the context of PF-associated lung diseases remains unexplored.

methodsTo determine the influence of c-MET in immune cells in the progression of pulmonary fibrosis, we used a conditional deletion of c-Met in immune cells. To induce pulmonary fibrosis mice were administered with bleomycin (BLM) intratracheally. Over the course of 21 days, mice were assessed for weight change, and after euthanasia at different timepoints, bronchoalveolar lavage fluid cells and lung tissue were assessed for inflammation and fibrosis. Furthermore, c-MET expression was assessed in cryobiopsy sections, bronchoalveolar lavage fluid cells samples and single cell RNA-sequencing dataset from human patients with distinct interstitial lung diseases.

resultsc-MET expression was induced in lung immune cells, specifically in T cells, interstitial macrophages, and neutrophils, during the inflammatory phase of BLM-induced PF mouse model. Deletion of c-Met in immune cells correlated with earlier weight recovery and improved survival of BLM-treated mice. Moreover, the deletion of c-Met in immune cells was associated with early recruitment of the immune cell populations, normally found to express c-MET, leading to a subsequent attenuation of the cytotoxic and proinflammatory environment. Consequently, the less extensive inflammatory response, possibly coupled with tissue repair, culminated in less exacerbated fibrotic lesions. Furthermore, c-MET expression was up-regulated in lung T cells from patients with fibrosing ILD, suggesting a potential involvement of c-MET in the development of fibrosing disease.

conclusionsThese results highlight the critical contribution of c-MET signaling in immune cells to their enhanced uncontrolled recruitment and activation toward a proinflammatory and profibrotic phenotype, leading to the exacerbation of lung injury and consequent development of fibrosis.

Indexed as

Mice, Inbred C57BLPneumoniaProto-Oncogene Proteins c-metPulmonary FibrosisAnimalsBleomycinDisease Models, AnimalFemaleHumansLungMaleMiceMice, KnockoutBleomycinMET protein, humanProto-Oncogene Proteins c-metBleomycinc-METILDsInflammationPulmonary fibrosis

Identifiers

PMID38909206
PMCPMC11193258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.